Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

5-alpha Avocuta active in seborrhea

Sep. 15, 2004

CollaGenex files for trademark Oracea for rosacea treatment Col-101

Sep. 15, 2004

Schering AG names new derma company Intendis

Sep. 14, 2004

Nucryst reports phase IIa results for NPI-32101 in atopic dermatitis

Sep. 10, 2004

Characterization of the antiinflammatory effects of topical tacrolimus in atopic dermatitis

Sep. 7, 2004

Clinical benefits of mepolizumab in eosinophilic skin disorders

Sep. 7, 2004

NDA submission for Aczone

Sep. 3, 2004

Good efficacy and safety profile found for XP-828L in mild to moderate psoriasis

Sep. 3, 2004

Ark signs marketing agreement with Teva for Keraboot in Israel

Sep. 1, 2004

Preliminary phase II results for XMP-629

Aug. 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.